CRT 2026

Panel Discussion | Update of Heart Failure Management

Moderator(s)

• 

  Jonathan Grinstein, MD

  Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation Physician
  University of Chicago
  MedStar Washington Hospital Center
  Bethesda, Maryland, United States

  Disclosure(s): CVRx: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• 

  Richa Gupta, MD

  Assistant Professor of Medicine, Advanced Heart Failure and Transplant Cardiology
  MedStar Health

  Disclosure(s): CVRx: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• PL

  Phillip H. Lam, MD

  Advanced Heart Failure Cardiologist
  MedStar Health

  Disclosure(s): No financial relationships to disclose
• 

  Ryan J. Tedford, MD

  Chief, Heart Failure; Peter C. Gazes Chair in Heart Failure
  Medical University of South Carolina, South Carolina, United States

  Disclosure(s): 35Pharma: Consulting Fees (e.g., advisory boards) (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed: travel reimbursement (Terminated, February 9, 2026); Acorai: Consulting Fees (e.g., advisory boards) (Ongoing); Adona: Consulting Fees (e.g., advisory boards) (Ongoing); Aria CV: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); CVRx: Travel to meeting (Terminated, February 9, 2026); Edwards Lifesciences LLC: Consulting Fees (e.g., advisory boards) (Ongoing); Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Fauna Bio: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Gradient: Consulting Fees (e.g., advisory boards) (Ongoing); Imbria: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Morphic: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Pulmonvant: Consulting Fees (e.g., advisory boards) (Terminated, February 9, 2026); Restore Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Tempus AI: Consulting Fees (e.g., advisory boards) (Ongoing); United Therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing)

Panel Discussant(s)

• 

  Jyothy John Puthumana, MD

  Professor
  Northwestern Medicine, Illinois, United States

  Disclosure(s): No financial relationships to disclose
• 

  Matthew Sherwood, MD, MHS

  System Director of Interventional Cardiology, Director of Structural Heart Program
  Inova Schar Heart and Vascular Institute, Virginia, United States

  Disclosure(s): Abbott Vascular, Medtronic, Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
• 

  Gregg W. Stone, MD, FACC, MSCAI

  Physician
  Mount Sinai
  New York, New York, United States

  Disclosure(s): Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter, Vascentis: Stock-privately held company (Ongoing); Cardiac Success, Occlutech, Ablative Solutions, Oxitope, Elixir, Impulse Dynamics, Asceneuron, Myochron, Vesalio: Consulting Fees (e.g., advisory boards) (Terminated); Colibri, Remote Cardiac Enablement, Valfix, Zoll, HeartFlow, Shockwave, Ancora, Adona Medical, Abbott, HighLife, Elucid Bio, Aria, Alleviant, FBR Medical, Bioventrix, MedHub, Biotyx Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Pulnovo, V-wave and PCORI via Weill Cornell Medical Center.: Grant/Research Support (Ongoing)